Fact sheet: UBS (L)E-Btech$

Fund information

Fund name
UBS (Lux) Equity - Biotech (USD) P Acc
Fund company manager
UBS AG
Fund type
SIB
Fund manager(s)
Nathalie Lötscher Petrus
since 30/11/2006
André Leue
since 22/11/2016
Fund objective
Actively managed equity portfolio investing worldwide in biotech companies. Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution. Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide. Investment decisions are based on a disciplined investment philosophy and fundamental research.
Benchmark
MSCI US Investable Market Biotechnology 10/40 Index
Investment style
None
Investment method
Shares

Performance snapshot

Sector
Fund
Sector
Fund
Sector
Fund

Quick stats

1 Year return

33.36 %

1 Year rank in sector

2/30

Sector

FO Equity - Pharma Health & Biotech

Yield
-
Fund size

£ 1.2 b

FE Risk score

228

NAV
-
Discount/Premium
-
Gearing
-

Top in sector

Holdings snapshot

  • USA
    93.23%
  • France
    2.16%
  • UK
    1.89%
  • International
    1.44%
  • Switzerland
    0.69%
  • Biotechnology/Medical
    100%
  • US Equities
    93.23%
  • French Equities
    2.16%
  • UK Equities
    1.89%
  • International Equities
    1.44%
  • Swiss Equities
    0.69%

Performance vs. Sector

Sector
Fund
Sector
Fund
Sector
Fund

Cumulative performance

1m6m1y3y5y
Fund0.81 %16.97 %33.36 %28.22 %134.59 %
Sector1.18 %8.1 %14.79 %27.68 %100.39 %
Rank within sector18 / 313 / 312 / 3013 / 284 / 24
Quartile th3 rd1 st1 st2 nd1 st

Calendar performance

YTD-20172016201520142013
Fund32.12 %-17.08 %1.57 %41.28 %54.62 %
Sector17.13 %-9.92 %7.24 %28.08 %41.03 %
Rank within sector3 / 3024 / 3024 / 284 / 255 / 24
Quartile th1 st4 th4 th1 st1 st

Risk statistics

Alpha-1.4
Beta1.52
Sharpe0.16
Volatility25
Tracking error12.2
Information ratio0.06
R-Squared0.87

Price movement

52 week high633.61
52 week low431.41
Current bid price0
Current offer price0
Current mid price621.88

Holdings by region

  • 93.23% USA
  • 2.16% France
  • 1.89% UK
  • 1.44% International
  • 0.69% Switzerland
  • 0.59% Belgium
  • 0% Others

Holdings by sector

  • 100% Biotechnology/Medical

Holdings by asset type

  • 93.23% US Equities
  • 2.16% French Equities
  • 1.89% UK Equities
  • 1.44% International Equities
  • 0.69% Swiss Equities
  • 0.59% Belgian Equities

Individual holdings

  • 9.89% CELGENE CORP
  • 7.56% ABBVIE INC
  • 7.56% GILEAD SCIENCES INC
  • 6.31% ALEXION PHARMACEUTICALS INC
  • 5.81% AMGEN INC
  • 4.55% VERTEX PHARMACEUTICAL
  • 4.24% INCYTE CORP
  • 4.17% BIOMARIN PHARMACEUTICAL
  • 3.52% ALNYLAM PHARMACEUTICALS INC
  • 2.97% REGENERON PHARMACEUTICALS INC